Identification of novel therapeutic targets for blocking acantholysis in pemphigus.

ABSTRACT:

Background and purpose

Pemphigus is caused by autoantibodies against desmoglein (Dsg) 1, Dsg3, and/or non-Dsg antigens. Pemphigus vulgaris (PV) is the most common manifestation of pemphigus, with painful erosions on mucous membranes. In most cases, blistering also occurs on the skin, leading to areas of extensive denudation. Despite improvements in pemphigus treatment, time to achieve remission is long, severe adverse events are frequent and 20% of patients do not respond adequately. Current clinical developments focus exclusively on modulating B cell function or autoantibody half-life. However, topical modulation of PV autoantibody-induced blistering is an attractive target because it could promptly relieve symptoms.

Experimental approach

To address this issue, we performed

SUBMITTER: Burmester IAK 

PROVIDER: S-EPMC7588822 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature